S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.84 (+1.06%)
AAPL   146.60 (+1.22%)
MSFT   307.35 (+1.03%)
FB   335.80 (+3.40%)
GOOGL   2,855.56 (+1.00%)
TSLA   871.51 (+3.38%)
AMZN   3,445.02 (+1.06%)
NVDA   222.21 (+1.64%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.21 (-1.05%)
GE   104.12 (-0.28%)
AMD   116.42 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:GLUE

Monte Rosa Therapeutics Stock Forecast, Price & News

$21.88
+0.68 (+3.21 %)
(As of 10/18/2021 03:59 PM ET)
Add
Compare
Today's Range
$20.81
$22.49
50-Day Range
$17.79
$42.21
52-Week Range
$17.39
$45.56
Volume6,481 shs
Average Volume242,235 shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLUE
Employees
60
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.01 billion
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

931st out of 1,361 stocks

Biological Products, Except Diagnostic Industry

143rd out of 196 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Monte Rosa Therapeutics (NASDAQ:GLUE) Frequently Asked Questions

Is Monte Rosa Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Monte Rosa Therapeutics stock.
View analyst ratings for Monte Rosa Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Monte Rosa Therapeutics?

Wall Street analysts have given Monte Rosa Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Monte Rosa Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Monte Rosa Therapeutics?

Monte Rosa Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totaling 2,530,000 shares, an increase of 30.4% from the September 15th total of 1,940,000 shares. Based on an average trading volume of 226,600 shares, the days-to-cover ratio is currently 11.2 days. Currently, 9.3% of the shares of the stock are short sold.
View Monte Rosa Therapeutics' Short Interest
.

When is Monte Rosa Therapeutics' next earnings date?

Monte Rosa Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Monte Rosa Therapeutics
.

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) announced its quarterly earnings results on Thursday, August, 12th. The company reported ($3.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $3.23.
View Monte Rosa Therapeutics' earnings history
.

What price target have analysts set for GLUE?

4 brokers have issued 1-year price objectives for Monte Rosa Therapeutics' stock. Their forecasts range from $20.00 to $40.00. On average, they expect Monte Rosa Therapeutics' share price to reach $32.00 in the next year. This suggests a possible upside of 46.7% from the stock's current price.
View analysts' price targets for Monte Rosa Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Monte Rosa Therapeutics' key executives?

Monte Rosa Therapeutics' management team includes the following people:
  • Dr. Markus Warmuth M.D., Pres, CEO & Director (Age 50, Pay $899.17k)
  • Mr. Ajim A. Tamboli C.F.A., CFA, Chief Financial Officer (Age 44, Pay $222.4k)
  • Ms. Jennifer Champoux, VP of Operations
  • Dr. Sharon Townson Ph.D., Chief Technology Officer (Age 46)
  • Dr. Owen B. Wallace, Chief Scientific Officer (Age 52)
  • Mr. Phil Nickson J.D., Ph.D., Head of Legal Operations
  • Dr. John C. Castle Ph.D., Chief Data Scientist (Age 50)
  • Ms. Jullian G. Jones J.D., M.B.A., Ph.D., Sr. VP & Head of Bus. Devel.
  • Dr. Silvia Buonamici Ph.D., Sr. VP of Drug Discovery Biology
  • Mr. Alexander Flohr, Sr. VP of Chemistry

When did Monte Rosa Therapeutics IPO?

(GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share.

What is Monte Rosa Therapeutics' stock symbol?

Monte Rosa Therapeutics trades on the NASDAQ under the ticker symbol "GLUE."

When does Monte Rosa Therapeutics' lock-up period expire?

Monte Rosa Therapeutics' lock-up period expires on Tuesday, December 21st. Monte Rosa Therapeutics had issued 11,700,000 shares in its initial public offering on June 24th. The total size of the offering was $222,300,000 based on an initial share price of $19.00. After the expiration of Monte Rosa Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Monte Rosa Therapeutics' stock price today?

One share of GLUE stock can currently be purchased for approximately $21.81.

How much money does Monte Rosa Therapeutics make?

Monte Rosa Therapeutics has a market capitalization of $1.01 billion.

How many employees does Monte Rosa Therapeutics have?

Monte Rosa Therapeutics employs 60 workers across the globe.

What is Monte Rosa Therapeutics' official website?

The official website for Monte Rosa Therapeutics is www.monterosatx.com.

How can I contact Monte Rosa Therapeutics?

The company can be reached via phone at 617-949-2643.


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.